中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Influencing factors for liver inflammation grade and fibrosis degree in patients with low-level HBV DNA

DOI: 10.3969/j.issn.1001-5256.2019.05.010
Research funding:

 

  • Received Date: 2018-10-26
  • Published Date: 2019-05-20
  • Objective To investigate liver pathological features and related factors in patients with low-level HBV DNA, and to provide a basis for evaluating the conditions of such patients. Methods A total of 137 patients with an HBV DNA level of < 2000 IU/ml and > 20 IU/ml who attended The Third People's Hospital of Kunming from January 2014 to December 2017 were enrolled. Liver pathological examination was performed for all patients. Of all patients, 44 had grade 1 ( G1) liver inflammation, 84 had grade 2 ( G2) liver inflammation, and 9 had grade 3 ( G3) liver inflammation; as for fibrosis stage, 2 had S0 fibrosis, 67 had S1 fibrosis, 56 had S2 fibrosis, 9 had S3 fibrosis, and 3 had S4 fibrosis. The correlation of liver inflammation grade and fibrosis stage with age, sex, duration of HBV infection, blood biochemistry, HBsAg level, and HBV DNA was analyzed. The Kruskal-Wallis H test was used for comparison of continuous data between multiple groups, the chi-square test was used for comparison of categorical data between groups, and univariate and multivariate one-way non-conditional logistic regression analyses were used to investigate the influencing factors for ≥G2 liver inflammation and ≥S2 fibrosis. Results There were significant differences in HBsAg, platelet count ( PLT) , diameter of the splenic vein, and spleen thickness between the G1, G2, and G3 groups ( H = 7. 135, 7. 458, 7. 588, and 10. 150, all P < 0. 05) , and there were also significant differences in HBsAg, PLT, diameter of the portal vein, diameter of the splenic vein, and spleen thickness between the S0, S1, S2, S3, and S4 groups ( H = 20. 564, 12. 065, 26. 171, 14. 720, and 13. 725, all P < 0. 05) . Of all 137 patients, 44 had no or mild inflammation and necrosis ( < G2 group) and 93 had moderate or severe inflammation and necrosis ( ≥G2 group) ; age, alanine aminotransferase, alkaline phosphatase ( ALP) , white blood cell count, diameter of the splenic vein, and spleen thickness, with statistical significance determined by the univariate logistic regression analysis, were included in the multivariate analysis ( α = 0. 15) , and the results showed that age ( odds ratio [OR]= 1. 045, P < 0. 05) , ALP ( OR = 1. 019, P < 0. 05) , and spleen thickness ( OR = 1. 150, P < 0. 05) were independent risk factors for ≥G2 liver inflammation in the patients with low-level HBV DNA. Of all 137 patients, 69 had no or mild liver fibrosis ( < S2 group) and 68 had moderate or severe liver fibrosis ( ≥S2 group) ; total bilirubin, HBsAg, PLT, and diameter of the portal vein, with statistical significance determined by the univariate logistic regression analysis, were included in the multivariate analysis ( α = 0. 15) , and the results showed that HBsAg ( OR = 2. 065) , PLT ( OR = 0. 988) , and diameter of the portal vein ( OR = 2. 464) were independent risk factors for ≥S2 liver fibrosis in the patients with low-level HBV DNA. Conclusion The majority of patients with low-level HBV DNA have the indication of antiviral therapy. Age, ALP, and spleen thickness are closely associated with liver inflammation grade in patients with low-level HBV DNA, and HBsAg, PLT, and diameter of the portal vein are closely associated with liver fibrosis.

     

  • [1] CHAN HL, WONG VW, WONG GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B[J]. Hepatology, 2010, 52 (4) :1232-1241.
    [2] THOMPSON AJ, NGUYEN T, LSER D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers:Disease phase influences correlation with viral load and intra-hepatic hepatitis B virus markers[J]. Hepatology, 2010, 51 (6) :1933-1944.
    [3] MONTAZERI G, RAHBAN M, MOHAMADNEJAD M, et al. Liver histology and HBV DN levels in chronically HBV infected patients with persistently normal alanine aminotransferase[J].Arch Iran Med, 2010, 13 (3) :193-202.
    [4] MACMAHON BJ. The natural history of chronic hepatitis B virus infection[J]. Hepatology, 2009, 49:45.
    [5] Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medcal Association. The guideline of prevention and treatment for chronic hepatitis B (2015 version) [J]. J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.
    [6] TSENG TC, LIU CJ, YANG HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads[J]. Hepatology, 2013, 57 (2) :441-450.
    [7] European Association for the Study of the Liver. EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J]. Hepatel, 2012, 57 (1) :167-185.
    [8] TRAN TT. Immune tolerant hepatitis B:A clinical dilemma[J].Gastroenterol Hepal, 2011, 7 (8) :511-516.
    [9] QIU HF, LI JH, YANG WJ, et al. Analysis of related factors of ALT persistently normal patients with chronic HBV infection[J]. Chin J Nosocomiol, 2015, 25 (17) :3893-3895. (in Chinese) 邱惠芳, 李金花, 杨文君, 等.慢性乙型肝炎感染谷丙转氨酶持续正常患者肝脏病理相关因素分析[J].中华医院感染杂志, 2015, 25 (17) :3893-3895.
    [10] LI W, XU KH, ZHAO SS. Association between liver pathology and clinical features in patients with chronic HBV infection and slightly elevated alanine aminotransferase[J]. J Clin Hepatol, 2017, 33 (11) :2123-2126. (in Chinese) 李伟, 徐葵花, 赵守松. ALT轻度升高的慢性HBV感染者临床特征与病理学的关系[J].临床肝胆病杂志, 2017, 33 (11) :2123-2126.
    [11] DING HB, LI YX, LAI JQ, et al. Correlation between pathological changes of liver tissue and portal vein diameter in patients with chronic hepatitis B[J]. J Prac Hepatol, 2010, 13 (5) :369-370. (in Chinese) 丁红兵, 李奕鑫, 赖江琼, 等.慢性乙型肝炎患者肝组织病理学改变与门静脉内径的相关性分析[J].实用肝脏病杂志, 2010, 13 (5) :369-370.
    [12] HUO XP, XIE QX, JIANG XP, et al. Pathological changes of liver tissues in 486 patients with chronic hepatitis B[J]. J Prac Hepatol, 2015, 18 (4) :360-363. (in Chinese) 霍雪平, 谢琴秀, 江晓平, 等. 486例慢性乙型肝炎患者肝组织病理学变化与肝功能指标的相关性研究[J].实用肝脏病杂志, 2015, 18 (4) :360-363.
    [13] SUN HY, WANG M, LYU SJ, et al. Predictive factors of early diagnosis of liver cirrhosis in chronic HBV carriers[J/CD].Chin J Liver Dis:Electronic Edit, 2017, 9 (4) :82-85. (in Chinese) 孙海英, 王明, 吕胜军, 等.慢性HBV携带者早期肝硬化诊断的预测因素分析[J/CD].中国肝脏病杂志:电子版, 2017, 9 (4) :82-85.
    [14] HUANG CM, YANG Z, NIE YQ, et al. Value of gamma-glutamyl transpeptidase-to-platelet ratioin predicting liver fibrosis stage in chronic hepatitis B patients in Guangdong, China[J]. J Clin Hepatol, 2018, 34 (6) :1204-1208. (in Chinese) 黄春明, 杨湛, 聂玉强, 等. GGT/PLT比值对广东地区慢性乙型肝炎患者肝纤维化分期的预测价值[J].临床肝胆病杂志, 2018, 34 (6) :1204-1208.
    [15] LU HY, LIU LF, XU XY, et al. FibroScan in diagnosis of liver fibrosis in patients with different chronic liver diseases:A comparative analysis[J]. J Clin Hepatol, 2016, 32 (8) :1512-1517. (in Chinese) .陆海英, 刘玲峰, 徐小元, 等. FibroScan诊断不同类型慢性肝病肝纤维化的效果比较[J].临床肝胆病杂志, 2016, 32 (8) :1513-1517.
  • Relative Articles

    [1]Xueyun GUO, Xuan ZHONG, Tingting ZHANG, Sihai CHEN, Wang ZHANG, Bimin LI, Xuan ZHU, Anjiang WANG. Risk factors for death within 30 days after admission in patients with decompensated liver cirrhosis and acute kidney injury and construction of a nomogram model[J]. Journal of Clinical Hepatology, 2024, 40(11): 2221-2228. doi: 10.12449/JCH241115
    [2]Naifan PAN, Xuesong SONG. Association between preoperative N-terminal pro-brain natriuretic peptide and acute kidney injury after liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(8): 1653-1660. doi: 10.12449/JCH240823
    [3]Jiaxuan HU, Tao HAN. An excerpt of Asian Pacific Association for the Study of the Liver clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1575-1578. doi: 10.12449/JCH240811
    [4]Yuan WEN, Juanjuan ZHU. Clinical efficacy of double plasma molecular absorption system and sequential plasma exchange combined with continuous renal replacement therapy in treatment of acute-on-chronic liver failure with acute kidney injury[J]. Journal of Clinical Hepatology, 2024, 40(3): 556-561. doi: 10.12449/JCH240319
    [5]Guiqiang WANG. Application and prospect of cell therapy in clinical treatment of liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(5): 1001-1003. doi: 10.3969/j.issn.1001-5256.2023.05.001
    [6]Gerui ZHU, Yani PI, Jing WANG, Kai HUANG, Yuan PENG, Gaofeng CHEN, Chenghai LIU, Yanyan TAO. Efficacy of Astragali Radix extract in treatment of a mouse model of aristolochic acid Ⅰ-induced liver and renal injury by regulating the IL-6/STAT3 signaling pathway[J]. Journal of Clinical Hepatology, 2023, 39(8): 1903-1910. doi: 10.3969/j.issn.1001-5256.2023.08.020
    [7]Peng WANG, Zeyu LI, Yating JIANG, Cheng SHANG, Hong WANG. Value of Model for End-Stage Liver Disease score and albumin-bilirubin score combined with β2-microglobulin in predicting liver cirrhosis with acute kidney injury[J]. Journal of Clinical Hepatology, 2023, 39(12): 2839-2844. doi: 10.3969/j.issn.1001-5256.2023.12.014
    [8]Mengyue SHANG, Yalin TONG, Yongzhong CHEN, Jie BAO. Influencing factors for acute kidney injury in acute liver failure and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2023, 39(2): 359-364. doi: 10.3969/j.issn.1001-5256.2023.02.016
    [9]Yan WANG, Mingzheng LI, Yufeng LIU, Shiming WANG. Early predictors for acute kidney injury in acute pancreatitis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1192-1197. doi: 10.3969/j.issn.1001-5256.2022.05.046
    [10]Yuanyuan JIN, Binghua ZHU, Xuejie FEI, Qian WANG. Clinical application of regional citrate anticoagulation in continuous renal replacement therapy for patients with liver failure[J]. Journal of Clinical Hepatology, 2021, 37(1): 200-203. doi: 10.3969/j.issn.1001-5256.2021.01.044
    [11]Hu Hui, Huang BeiBei, Ning Ling, Jiang ShouWei, Shen Qiang, Liu Lei, Li Lei. Establishment and evaluation of a predictive model for short-time prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(1): 123-127. doi: 10.3969/j.issn.1001-5256.2020.01.027
    [12]CHEN YuQing, JIANG Xin, XU Huan, ZHONG Rui, LI PeiLing, ZHANG Lu, PENG Yan, TANG XiaoWei. Value of serum cystatin C in predicting acute kidney injury in patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(11): 2505-2508. doi: 10.3969/j.issn.1001-5256.2020.11.021
    [13]CHEN WenJi, LIANG Wei, ZHOU YongJian. Acute kidney injury and hepatorenal syndrome in end-stage liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2423-2428. doi: 10.3969/j.issn.1001-5256.2020.11.006
    [14]Li Ming, Chen RuLi, Wu ZhenPing, Cheng XiaoYu, Mei Qing, Zhang LunLi, Li XiaoPeng. Value of combined measurement of urinary insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinases-2 in predicting acute kidney injury associated with HBV-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(7): 1560-1564. doi: 10.3969/j.issn.1001-5256.2019.07.027
    [15]Yao YunHai, Gan JianHe, Zhao WeiFeng. Effect of plasma exchange combined with continuous renal replacement therapy on the prognosis of patients with HBV-related acute-on-chronic liver failure and acute kidney injury[J]. Journal of Clinical Hepatology, 2019, 35(5): 1065-1069. doi: 10.3969/j.issn.1001-5256.2019.05.026
    [16]Lei Lei, Li LiangPing, Zhang Hu. Value of combined measurement of serum cystatin C and urinary neutrophil gelatinase-associated lipocalin in diagnosis of acute kidney injury secondary to cirrhotic ascites[J]. Journal of Clinical Hepatology, 2018, 34(1): 101-105. doi: 10.3969/j.issn.1001-5256.2018.01.021
    [17]Chen Li, Mei Yong, Yang YiBin, Cao MingYan. Research advances in renal replacement therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2016, 32(3): 605-608. doi: 10.3969/j.issn.1001-5256.2016.03.046
    [18]Wan ZhiHong, Wang JianJun, Xie GuoMing, You ShaoLi, Liu HongLing, Zhu Bing, Zang Hong, Xin ShaoJie. Significance of serum cystatin C level for early diagnosis of acute kidney injury in patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2014, 30(7): 666-669. doi: 10.3969/j.issn.1001-5256.2014.07.024
    [19]Cai JunJun, Han Tao. Diagnosis and treatment of acute kidney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1352-1356. doi: 10.3969/j.issn.1001-5256.2014.12.030
  • Cited by

    Periodical cited type(20)

    1. 朱宏坤,戴芳芳,钱世宁. 血必净注射液对行连续性肾脏替代疗法的多器官功能障碍综合征患者凝血功能的影响. 哈尔滨医科大学学报. 2024(01): 75-79 .
    2. 肖晶晶. 局部枸橼酸抗凝联合CRRT治疗脓毒症合并急性肾衰竭的临床疗效及对患者凝血功能的影响. 延边大学医学学报. 2024(05): 534-537 .
    3. 王娟,张丽萍,丁童,卫淑润,翁志华. 局部枸橼酸抗凝血液净化技术在ICU造血干细胞移植后弥漫性肺泡出血患者治疗中应用价值. 临床军医杂志. 2023(05): 522-524 .
    4. 孙卫和,许伟伟,冒秀宏,汪涛. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用. 中外医疗. 2023(18): 129-132 .
    5. 赵志强,孟鹏飞,石正松,陈亚君,肖宏涛. 枸橼酸抗凝在脓毒症伴高危出血行连续性肾脏替代治疗患者中的应用效果. 医药论坛杂志. 2023(19): 14-18 .
    6. 李一青,白银果,沙莎. 连续性静脉-静脉血液滤过透析和局部枸橼酸抗凝在重症患者乳酸升高时应用的有效性和安全性研究. 贵州医药. 2023(11): 1704-1705 .
    7. 张妍,荣阳,张芳. CRRT治疗肾衰竭合并顽固性心力衰竭的临床效果. 中西医结合心脑血管病杂志. 2022(02): 285-288 .
    8. 张竞葳,田敏,余建斌. 局部枸橼酸抗凝应用于维持性血液透析合并消化道出血患者的疗效观察. 现代医学与健康研究电子杂志. 2022(13): 130-134 .
    9. 陈伟玲,邓虹,黄颖妍,李乐,张洪举. 局部枸橼酸抗凝在连续性肾替代疗法治疗中的效果及安全性指标的变化. 北方药学. 2022(05): 116-119 .
    10. 吴允东,江海娇,张伟,曹迎亚,杨尚志,周伟. 不同抗凝方案用于心脏术后患者连续性肾脏替代治疗中的效果. 皖南医学院学报. 2022(05): 436-439+443 .
    11. 严海燕,黄雪敏,李大亮,岑树坤,蒋林青. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用分析. 实用中西医结合临床. 2022(17): 31-33+37 .
    12. 金源源,诸炳骅,费雪洁,王倩. 局部枸橼酸抗凝在肝衰竭患者连续性肾脏替代治疗中的应用. 临床肝胆病杂志. 2021(01): 200-203 . 本站查看
    13. 胡新,毛智,周飞虎. 枸橼酸抗凝在重症患者连续血液净化中的应用进展. 武警医学. 2021(01): 78-81 .
    14. 杨向莎,杨福燕,张瑞霞,张军. 改良式枸橼酸钠与低分子量肝素在急性肾损伤CRRT中的抗凝效果比较. 临床医学研究与实践. 2021(20): 46-49 .
    15. 冉梦晓,陈辉,郑浩天. 枸橼酸局部抗凝技术在血液透析中的应用进展. 中国医药. 2021(07): 1113-1116 .
    16. 杨妮娜,李之诉,杨禄,陈王峰. RCA-CRRT治疗中滤器后离子钙与体内离子钙的相关性. 现代实用医学. 2021(08): 993-995 .
    17. 焦清海,郑丽环,张雪梅,王征,杜菲,陈亮. 局部枸橼酸抗凝在危重症患者持续肾脏替代疗法中的临床应用. 河北医科大学学报. 2021(10): 1144-1148 .
    18. 王敬文. 枸橼酸与肝素抗凝对重症血液净化患者临床指标和安全性的影响比较. 中外医学研究. 2021(32): 40-43 .
    19. 冯菁,李和文,张兴凯,王建华,张作鹏,郭燕蓉,任航奇. 肝衰竭患者行局部枸橼酸抗凝连续性肾脏替代治疗时发生枸橼酸蓄积的影响因素分析. 临床和实验医学杂志. 2021(22): 2402-2406 .
    20. 李杨,由丽丽. 连续性肾脏替代治疗脑出血合并急性肾损伤患者中应用局部枸橼酸抗凝治疗的有效性及安全性. 中国医药指南. 2020(36): 89-90 .

    Other cited types(1)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1798) PDF downloads(336) Cited by(21)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return